Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Regenxbio
Thumbnail
May 12, 2022

Opportunities arise for once-spurned partners

Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?

Thumbnail
February 24, 2022

Amicus exits gene therapy

Spac backtrack confirms that the gene therapy bubble has burst

Article image
Vantage logo
February 14, 2022

Angiogenesis 2022 – Regeneron and Bayer see positive signs for long-acting Eylea

The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold?

Article image
Vantage logo
September 14, 2021

The picture worsens for Astellas’s gene therapy

Article image
Vantage logo
September 13, 2021

Abbvie puts first toe in gene therapy, courtesy of Regenxbio

Article image
Vantage logo
July 26, 2021

MPS 2021 – Denali disappoints in Hunter syndrome

The group will need longer-term data to justify its huge valuation.

Article image
Vantage logo
July 23, 2021

Adverum eyes disaster

Article image
Vantage logo
July 22, 2021

Roche takes the Tim-3 battle to Novartis

The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.

Article image
Vantage logo
July 01, 2021

Pharming turns to gene therapy for next-gen HAE therapy

Article image
Vantage logo
June 30, 2021

Biotech’s important upcoming data

Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.

Article image
Vantage logo
June 16, 2021

Clearside’s long-acting eye project shows promise

But data are early, and other groups are also developing less frequent injections for wet AMD.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 12, 2022

Q2 Roundup Infographic

August 10, 2022

Q2 Roundup eBook

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.